Data are available from the Danish national rheumatolgic quality registry, DANBIO, for researchers who meet the Danish legal criteria for access to confidential data. Contact: <databasen@danbio-online.dk> or [www.rkkp.dk](http://www.rkkp.dk).

Introduction {#sec005}
============

Pain in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other spondyloarthritis (SpA) is traditionally considered to be of peripheral nociceptive origin, i.e. pain elicited by activation of afferent sensory nerve fibers (C-fibers) in the inflamed synovium \[[@pone.0180014.ref001]\]. Increased responsiveness of peripheral and central nociceptive neurons, i.e. pain hypersensitivity, is a normal response (neuroplasticity) in the presence of inflammation. However, pain hypersensitivity may persist after the inflammation has ceased and thus become a manifestation of maladaptive pathological changes in the central nervous system leading to chronic pain \[[@pone.0180014.ref002]\].

Chronic pain has been most thoroughly investigated in RA where pain is reported to persist despite regression of inflammatory signs \[[@pone.0180014.ref003]\] and emerging data suggest a role of augmented central pain processing, including central sensitization and dysfunction of descending pain modulating systems in subsets of patients \[[@pone.0180014.ref004]\]. Fibromyalgia (FM), by many considered the prototypical central pain syndrome, is more common in RA than in the general population with reported prevalence estimates of up to 20% \[[@pone.0180014.ref005]\]. A co-diagnosis of FM in RA is associated with poorer outcome of anti-inflammatory treatment when evaluated by pain ratings and composite disease activity scores \[[@pone.0180014.ref005];[@pone.0180014.ref006]\]. However, it is likely that not only individuals with RA and concomitant FM have abnormal central pain processing. There is probably a continuum of pain hypersensitivity among patients with RA that may influence patient-reported outcomes and disease activity evaluations \[[@pone.0180014.ref006]\]. Subserving pain mechanisms in PsA and SpA are less well examined and studies have mainly focused on co-occurrence of FM. The reported prevalence of FM ranges from 4% to 15% for SpA and 17% to 53% for PsA depending on screening tool and gender \[[@pone.0180014.ref007]--[@pone.0180014.ref011]\].

Treatment of inflammatory arthritis is based on disease activity measures that are fully or partially composed of subjective indicators related to pain perception. Pain hypersensitivity may lead to continuous high reports of for example tender joints, pain and poor global health and thus an overestimation of inflammatory activity. Identification of possible underlying pain mechanisms may, therefore, be of great importance and assist clinical decision making. The painDETECT questionnaire (PDQ) is a patient administered screening questionnaire originally developed to identify neuropathic pain \[[@pone.0180014.ref012]\]. Based on pain phenotypic similarities, the PDQ has been used to assess neuropathic pain features as a proxy of central pain mechanisms in patients with osteoarthritis and fibromyalgia \[[@pone.0180014.ref013]--[@pone.0180014.ref018]\]. Recently, the PDQ has also been introduced in studies of smaller samples of patients with RA \[[@pone.0180014.ref019];[@pone.0180014.ref020]\] and SpA \[[@pone.0180014.ref021]\] reporting neuropathic pain features in subsets of patients.

The purpose of this study was to report the prevalence of pain phenotypes (non-neuropathic vs. neuropathic pain features) as assessed by the PDQ in the Danish arthritis population (RA, PsA and other SpA) and to investigate the association between pain phenotype and inflammation. Furthermore, the study aimed to describe differences in patient characteristics across PDQ-classification groups.

Patients and methods {#sec006}
====================

Study design and setting {#sec007}
------------------------

The study was designed as a descriptive, cross sectional survey including patients registered in DANBIO, the Danish nationwide rheumatologic registry (Protocol; <http://parkerinst.dk/research>). The DANBIO-registry is a clinical quality assurance registry which was initiated in year 2000. It is based on Danish rheumatologists registering and continuously reporting data on their patients diagnosed with inflammatory arthritis when seen in daily care. It covers \>90% of adults treated with biologics due to rheumatic disease and data on patients treated with disease-modifying antirheumatic drugs, DMARDs, are also collected \[[@pone.0180014.ref022]--[@pone.0180014.ref024]\].

Following local approval of the project at the departments, an electronic version of the PDQ was implemented nationally on the DANBIO touch screens in the waiting room at 22 of 24 departments of Rheumatology in Denmark for a period of six months (1.Dec 2013-1.June 2014). All patients registered as having any form of RA, PsA, other SpA, unspecific arthritis (UA) or 'no diagnosis' were eligible and invited to participate in the survey. Patients were asked to accept participation, decline or indicate 'no pain 4 weeks prior to the survey' on the touch screens. Patients choosing the two latter categories were excluded from filling in the PDQ, while clinical data from DANBIO were obtainable from all patients visiting the touch screens in the study period.

The primary focus was on the diagnostic groups: RA, PsA and other SpA. All patients were included in the overall pain analysis, while only patients with a complete PDQ response were included in the PDQ subanalyses. The first complete questionnaire and corresponding clinical data from the same date were extracted for analyses (CRP +/- 14 days).

Patient consent was obtained on the touch screen prior to the redirection to the PDQ. According to Danish legislation, surveys do not require approval by Ethics Committees and registrations and publications of data from clinical registries do not require patient consent or approval by Ethics Committees. Approval was obtained from the Danish Data Protection Agency.

Variables and outcome measures {#sec008}
------------------------------

The PDQ is a symptom-based assessment tool originally developed to assist identification of neuropathic pain in patient with low back pain \[[@pone.0180014.ref012]\]. It is composed of items reflecting pain intensity (three numeric rating scales), pain course pattern, a pain drawing intended for indication of pain radiation, and seven questions describing somatosensory signs and symptoms considered characteristic for neuropathic pain rated on a six-category Likert scale (from never to very strongly). A total score ranging from -1 to 38 is calculated based on the patient's answers. Pain intensity ratings are not included in the total score; selection of pain course pattern contributes to the total score with a value ranging from -1 to 1; the absence/presence of radiating pain with a value of 0 or 2; and the presence and severity of evaluated somatosensory signs and symptoms with a value ranging from 0 to 35. For diagnostic purposes, a validated algorithm is used to classify pain into three groups: a score \>18 indicate that presence of a predominant neuropathic pain component is likely, a score \<13 indicated that it is not, while a score of 13--18 is considered indecisive; i.e., a neuropathic pain component cannot be ruled out. \[[@pone.0180014.ref012]\]. The questionnaire is reported to have a sensitivity of 84% and likewise a specificity of 84% (electronic version) when applied for pain classification in a mixed chronic pain population \[[@pone.0180014.ref012]\]. Satisfactory psychometric properties of the PDQ have been demonstrated within osteoarthritis by Morton et al.\[[@pone.0180014.ref025]\], and within inflammatory arthritis by our group (in review).

Information on demographics and treatment were registered according to the DANBIO registry standard. Before consulting their rheumatologist patients regularly complete commonly used standardized patients reported outcomes ([Table 1](#pone.0180014.t001){ref-type="table"}) on the DANBIO touch screens in the doctor's waiting room. All patients complete visual analogue scale (VAS) pain, VAS fatigue, and VAS global health, which are 0--100 mm scales, where 100 mm indicates the worst imaginable pain/fatigue/ general health. Depending on their diagnosis patients furthermore complete a disability index. For patients with peripheral joint disease the health assessment questionnaire (HAQ)\[[@pone.0180014.ref026]\], an index reflecting level of function in daily living is used. For patients with axial joint disease the Bath ankylosing spondylitis function index (BASFI) is used \[[@pone.0180014.ref027]\]. Finally the Bath ankylosing spondylitis disease activity index (BASDAI) is used to register overall disease activity in this patient group \[[@pone.0180014.ref028];[@pone.0180014.ref029]\]. The two latter questionnaires include questions on pain, disability and function related to the axial and large joints. The rheumatologists register corresponding clinical outcomes hence different disease activity scores are available in the DANBIO registry:

DAS28-crp (disease activity score 28 joints--CRP) \[[@pone.0180014.ref030]\] used for peripheral joint disease: $$\underline{0.56*\left. \sqrt{}\ \left( TJC28 \right)+0.28*\left. \sqrt{}\ \left( SJC28 \right)+0.36*ln⁡\left( CRP+1 \right)+0.014*GH+0.96 \right. \right.}$$

ASDAS (ankylosing spondylitis disease activity score) \[[@pone.0180014.ref031]\] used for axial joint disease: $$\underline{0.12*Back\ Pain+0.06*Duration\ of\ Morning\ Stiffness+0.11*Patient\ Global+0.07*Peripheral\ Pain/Swelling+0.5\ Ln\ \left( CRP+1 \right)}$$

10.1371/journal.pone.0180014.t001

###### Overview of patient reported outcome measures and disease activity scores available in the DANBIO registry.

![](pone.0180014.t001){#pone.0180014.t001g}

  Variable            Collected in disease area   Unit and range[\*](#t001fn001){ref-type="table-fn"}   Aims to assess             Nature of variable[^\#^](#t001fn004){ref-type="table-fn"}
  ------------------- --------------------------- ----------------------------------------------------- -------------------------- -----------------------------------------------------------
  VAS pain            RA/PsA/SpA                  0--100 mm                                             Pain intensity             Self-reported
  VAS fatigue         RA/PsA/SpA                  0--100 mm                                             Fatigue severity           Self-reported
  VAS global health   RA/PsA/SpA                  0--100 mm                                             Impact on global health    Self-reported
  HAQ                 RA/PsA                      0--3                                                  Disability                 Self-reported
  BASMI               PsA/SpA                     0--100[\*\*](#t001fn002){ref-type="table-fn"}         Spinal mobility            Clinical examination
  BASFI               PsA/SpA                     0--100[\*\*](#t001fn002){ref-type="table-fn"}         Disability                 Self-reported
  BASDAI              PsA/SpA                     0--100[\*\*](#t001fn002){ref-type="table-fn"}         Overall disease activity   Self-reported
  DAS28-CRP           RA /PsA                     0--10                                                 Overall disease activity   Combination
  ASDAS               PsA/SpA                     0--6.3[\*\*\*](#t001fn003){ref-type="table-fn"}       Overall disease activity   Combination

\*No unit specified indicates an arbitrary unit

\*\* As used in the DANBIO registry

\*\*\*Maximum scores on all self-reported items (0--10) and CRP 100.

\# The nature can be either: Self-reported, clinical examination or a combination of variables that are self-reported, objective and the result of a clinical examination

BASMI-365 (Bath ankylosing spondylitis metrology index undertaken within the last year) \[[@pone.0180014.ref032]\]: a standardized clinical examination reporting degree of joint stiffness.

Statistical analysis {#sec009}
--------------------

SAS software (version 9.3; SAS Institute Inc., Cary; North Carolina, USA) was used for the statistical analyses. The PROC UNIVARIATE statement was used for visual inspection of the distribution of variables. Potential group differences were tested using the non-parametric Kruskal-Wallis test for continuous variables and Chi-square test for categorical variables. Correcting for multiple testing (65 repeated tests) two-sided p-values \< 0.001 (0.05/65) were regarded as statistically significant when comparing potential PDQ classification-group differences. Due to the 'real life' character of DANBIO complete data for all variables were not available. Only available data were used for calculations.

To address the possible presence of sensitization in more ways also the swollen to tender joint count ratio (STR) was calculated according to previously published procedures \[[@pone.0180014.ref033]\] and compared across PDQ classification-groups using the PROC FREQ procedure.

To quantify a potential increased risk for rating higher than or equal to the median VAS-pain associated with the PDQ classification-groups (\<13 = low, 13--18 = intermediate, \>18 = high) logistic regression analysis was performed. For pragmatic reasons the median VAS for PDQ-completers was chosen as cut off (39 mm). Prior to conducting the logistic regression, an analysis of possible interaction between the PDQ classification-group and diagnosis was performed, which proved insignificant (y = 'diagnosis' 'PDQ classification-group' 'diagnosis\*PDQ classification-group' (interaction); p-value for interaction = 0.76, p-value for PDQ 'classification-group' \<0.001, p-value for 'diagnosis' \< 0.001). Hence, the 'PDQ classification-group' and 'diagnosis' were applied as main effects in the unadjusted Model 1. Separate models were run for each pain classification and disease comparison. Based on clinical significance and plausibility the following a priori selected confounders were included in the adjusted Model 1: sex, age, disease duration, CRP, and status of treatment with biologics (yes/no). Accepted level of covariance between independent variables was Spearman's Rho \< 0.3. Backward deletion of variables with a p-value \> 0.1 was performed to make a more parsimonious adjusted model (Model 2). Results from the logistic regression analyses are reported as odds ratios with confidence intervals (95%CI).

Results {#sec010}
=======

Flow of respondents and sampling process {#sec011}
----------------------------------------

[Fig 1](#pone.0180014.g001){ref-type="fig"} illustrates the patient flow. A total of 15,978 patients belonging to either of the following diagnostic groups; RA, PsA, other SpA, unspecific arthritis (UA) or 'no diagnose' were invited to participate in the study (visited the touch screens in the period). Standard clinical data from DANBIO were available on these patients. Of those 7,918 accepted to fill in the PDQ and 7,054 completed all items in the questionnaire and were assigned a score. A total of 6,133 patients declined participation, while 1,927 registered themselves as being pain-free, thus principally excluding themselves from filling in the PDQ. The median (IQR) level of VAS pain reported as standard in the DANBIO-registry for all invited participants was 31 (14--55) mm, 39 (21--63) mm for PDQ-completers, 30 (14--53) mm for declining participants and 8 (2--20) mm for participants categorizing themselves as pain-free in the introductory touch screen form. Of all patients visiting the touch screen 52% (7,483/14,339) had a VAS pain ≥ 30 mm while the numbers were 63% (3,991/6,380) among PDQ-completers, 51% (2,799/5,471) for declining participants and 15% (262/1,712) for participants reporting to be pain-free.

![Flowchart of possible participants in the painDETECT survey.\
RA: rheumatoid arthritis; PsA: psoriatic arthritis; SpA: other Spondyloarthritis; UA unspecified arthritis; Dx: diagnosis.](pone.0180014.g001){#pone.0180014.g001}

PDQ classification across arthritis diagnoses {#sec012}
---------------------------------------------

The main results of this study, the distribution of the PDQ classification-groups (\<13/ 13-18/ \>18), are illustrated in [Fig 2](#pone.0180014.g002){ref-type="fig"}. More than 20% across all diagnoses had a PDQ score \> 18 indicative of primarily neuropathic pain features. A total of 28% of PsA patients had a PDQ scores \> 18 which was significantly higher than for patients with RA and SpA (p\<0.001). Also statistically significantly fewer PsA patients had a PDQ score \< 13 (p\<0.001) indicating primarily non-neuropathic pain.

![Distribution of painDETECT classification-groups (\<13/ 13-18/ \>18).\
\* p \< 0.001.](pone.0180014.g002){#pone.0180014.g002}

Participant demographics and clinical characteristics {#sec013}
-----------------------------------------------------

Patient characteristics stratified by PDQ-score are shown in [Table 2](#pone.0180014.t002){ref-type="table"}. Treatment with DMARDs included: methotrexate (MTX), sulfasalazine, leflunomide, chloroquine and azathioprine. Treatment with Biologics primarily included one of the following agents: infliximab, eternacept, adalimumab, golimumab, certolizumab, abatacept, tocilizumab, or rituximab. MTX in either mono or combination therapy was used in 71% of RA, 58% of PsA and 15% of SpA patients.

10.1371/journal.pone.0180014.t002

###### Patient characteristics stratified by painDETECT classification-group.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                             \     n\                                          \                    [PDQ score]{.ul}\   \                  \
                                                                                  \<13                 13--18              \>18               P-value
  ----------------------------- ----- ------------------------------------------- -------------------- ------------------- ------------------ ---------------------------------------------
  **Demographics**                                                                                                                            

  Patients, total (n)           RA    3826                                        2136                 903                 787                \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1180                                        527                  321                 332                \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   1093                                        598                  268                 227                \<0.001[†](#t002fn003){ref-type="table-fn"}

  Female sex n(%)^a^            RA    2766                                        1455 (68)            674 (75)            637 (81)           \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   666                                         235 (45)             193 (60)            238 (72)           \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   436                                         194(32)              123 (46)            119 (52)           \<0.001[†](#t002fn003){ref-type="table-fn"}

  Age (yrs)                     RA    3826                                        61 (52--69)          59 (51--67)         59 (51--66)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1180                                        53 (43--61)          52 (44--60)         52 (42--60)        0.227

                                SpA   1093                                        45 (36--55)          45 (37--55)         43 (36--53)        0.213

  Disease duration^b^           RA    3470                                        8(3--16)             8(3--15)            8(3--15)           0.573

                                PsA   1000                                        7 (3--12)            5 (2--10)           5 (2--10)          0.004

                                SpA   953                                         7 (3--15)            5 (2--10)           4 (2--10)          0.001

  **Treatment intensity**                                                                                                                     

  DMARDS n(%)                   RA    3216                                        1829(86)             749(83)             647(82)            0.035

                                PsA   792                                         349(66)              222(69)             221(67)            0.656

                                SpA   237                                         122(20)              62(23)              53(23)             0.527

  DMARDS\>1^c^                  RA    777                                         395(18)              197(22)             185(24)            0.005

                                PsA   79                                          27 (5)               25(8)               27(8)              0.150

                                SpA   18                                          12 (2)               3 (1)               3 (1)              0.581

  Current bio n(%)              RA    1341                                        730(34)              328(36)             283(36)            0.439

                                PsA   458                                         212(40)              121(38)             125(38)            0.670

                                SpA   646                                         362 (61)             153(57)             131 (58)           0.566

  Bio \>1^d^                    RA    875                                         422 (50)             240 (59)            213 (59)           0.002

                                PsA   263                                         88 (36)              72 (51)             103 (61)           \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   349                                         162(40)              93 (49)             94 (59)            0.003

  DMARDs previous bio^e^        RA    204                                         80 (4)               60 (7)              64 (8)             \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   59                                          20 (4)               13(4)               26(8)              0.020

                                SpA   11                                          7 (1)                7(3)                4 (2)              0.302

  Prednisolone n(%)             RA    376                                         188 (9)              87 (10)             101 (13)           0.005

                                PsA   28                                          12 (2)               6 (2)               10 (3)             0.619

                                SpA   11                                          8 (1)                2 (1)               1 (0.5)            0.456

  **PROs**                                                                                                                                    

  VAS pain                      RA    3508                                        26 (14--44)          43 (27--61)         61 (43--77)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1071                                        27 (15--46)          49.5 (29--69)       69 (52--81)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   995                                         30 (16--53)          53 (36--71)         68.5 (52--82)      \<0.001[†](#t002fn003){ref-type="table-fn"}

  VAS fatigue                   RA    3508                                        34 (17--57)          54 (34--72)         72 (54--85)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1070                                        35 (17--57)          63.5 (40--80)       78 (62--90)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   995                                         40 (22.5--66)        65 (41.5--81)       77 (60--88)        \<0.001[†](#t002fn003){ref-type="table-fn"}

  VAS GH                        RA    3522                                        29 (15--53)          51 (31--68)         70 (52--84)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1071                                        30 (15--57)          58 (34--78)         77 (59--89)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   994                                         33.5 (19--56)        63 (39.5--77.5)     75 (59--87)        \<0.001[†](#t002fn003){ref-type="table-fn"}

  HAQ                           RA    3506                                        0.5 (0.125--1)       1 (0.5--1.375)      1.375(1--1.875)    \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   1046                                        0.375(0.125--0.75)   0.875(0.5--1.375)   1.375(1--1.875)    \<0.001[†](#t002fn003){ref-type="table-fn"}

  BASDAI                        PsA   1002                                        29 (15--46)          53 (36--68)         70 (55--83)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   923                                         31.5 (17--48)        53 (35--66)         68 (53--79)        \<0.001[†](#t002fn003){ref-type="table-fn"}

  BASFI                         PsA   1001                                        22 (8--38)           42.5 (26--61)       65 (46--81)        \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   921                                         23 (11--43)          38 (21--58)         58 (41--77)        \<0.001[†](#t002fn003){ref-type="table-fn"}

  **Disease activity scores**                                                                                                                 

  VAS doctor                    RA    3058                                        7 (3--14)            10 (4--19)          13 (6.5--26)       \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   900                                         8 (3--15)            10 (5--20)          15 (7--25)         \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   609                                         6 (2--15)            9 (4--16)           12 (5--25)         \<0.001[†](#t002fn003){ref-type="table-fn"}

  DAS28-CRP                     RA    3046                                        2.4 (1.9--3.3)       3(2.3--3.9)         3.7 (2.8--4.7)     \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   825                                         2.4 (1.8--3.0)       3.1(2.3--3.9)       3.7 (2.7--4.6)     \<0.001[†](#t002fn003){ref-type="table-fn"}

  SJC                           RA    3282                                        0 (0--1)             0 (0--2)            0 (0--2)           \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   946                                         0 (0--0)             0 (0--1)            0 (0--1)           0.007

  TJC                           RA    3295                                        0 (0--2)             1 (0--5)            4 (0--9)           \<0.001[†](#t002fn003){ref-type="table-fn"}

                                PsA   956                                         0 (0--2)             1 (0--4)            4 (0--9)           \<0.001[†](#t002fn003){ref-type="table-fn"}

  ASDAS                         PsA   823                                         2 (1.4--2.7)         2.6 (2.1--3.55)     3.45 (2.7--3.95)   \<0.001[†](#t002fn003){ref-type="table-fn"}

                                SpA   697                                         2 (1.4--2.8)         2.9 (2.2--3.3)      3.2 (2.6--3.9)     \<0.001[†](#t002fn003){ref-type="table-fn"}

  BASMI-365                     PsA   299                                         10 (0--20)           10 (0--30)          20 (10--30)        0.004

                                SpA   921                                         10 (0--40)           20 (10--30)         20 (10--40)        0.010

  **Biochemistry**                                                                                                                            

  CRP mg/l                      RA    3231                                        4 (2--9)             4 (1--9)            4 (2--10)          0.067

                                PsA   914                                         3 (1--6)             3 (1--7)            4 (2--7)           0.446

                                SpA   775                                         3 (1--7)             3 (1--7)            3 (1--8)           0.736

  RF n(%)                       RA    3091[\*](#t002fn004){ref-type="table-fn"}   1388 (78)            575 (78)            455 (78)           0.968

  antiCCP n(%)                  RA    1908[\*](#t002fn004){ref-type="table-fn"}   579 (53)             221 (48)            173 (48)           0.122

  HLA-B27 n(%)                  PsA   128[\*](#t002fn004){ref-type="table-fn"}    36 (60)              21 (58)             13 (41)            0.180

                                SpA   367[\*](#t002fn004){ref-type="table-fn"}    167 (82)             61 (71)             45 (58)            0.002
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All values are the median (Q1-Q3) unless otherwise specified. Group differences were tested using Kruskal-Wallis test or Chi-square test.

a: Refers to the fraction of women in each subgroup of PDQ classification. b: Time since diagnosis. c: Receives a combination of DMARDs. d: Have received more than one biologic agent. e: Currently treated with DMARDs and previously treated with a biologic agent.

† Remain significant after adjusting for multiple testing.

\*Number of patients with available information (pos/neg).

PDQ-score: painDETECT Questionnaire score; DMARDs: disease modifying anti-rheumatic drugs; Bio: biological agent; PROs: patient reported outcomes; VAS: visual analogue scale (mm); GH: global health; DAS28-CRP: disease activity score 28 joints; CRP: C- reactive protein; SJC: swollen joint count; TJC: tender joint count. HAQ: health assessment questionnaire; ASDAS: ankylosing spondylitis disease activity score; BASDAI: Bath ankylosing spondylitis disease activity index; BASMI 365: Bath ankylosing spondylitis metrology index attained within the last year; RF: rheumatoid factor; antiCCP: cyclic citrullinated peptide antibody; HLA-B27: human leucocyte antibody, subtype B27.

A higher number of women was observed in the higher PDQ classification-groups along with higher absolute values of all patient reported outcomes e.g. patient's scores for pain, fatigue, global health and disability (HAQ, BASFI), doctor's global score and disease activity scores for the three diseases (DAS28-CRP, BASDAI, ASDAS). There were no differences across PDQ classification-groups in CRP, serology and current treatment with a biological agent. Furthermore, the median swollen joint count (SJC) was 0 for all categories; however the interquartile range varied slightly (p\<0.001).

Some differences across PDQ classification-groups only related to one of the diagnoses:

In patients with RA, higher tender joint count (TJC) and number of patients currently treated with DMARD and previously treated with Biologics were observed in the higher PDQ classification-group, while age was higher in the low PDQ classification-group.

In PsA patients higher absolute values in the higher PDQ-classification-groups for TJC and higher fraction of patients treated with more than one biological drug were seen.

In patients with other SpA a lower proportion of HLA-B27 positive patients was observed in the higher PDQ classification-groups, though not (borderline) statistical significant.

Finally, a stratified analysis of the number of biologic agents received by the patients (first, second, third or fourth or more) did not reveal any differences.

BMI only differed across PDQ-classification-groups for RA-patients (p\<0.001), where a higher value was observed in the higher classification-groups, while no difference in smoking habits was observed for any diagnosis (data not shown).

Swollen to tender joint count ratio {#sec014}
-----------------------------------

The proportions of STR groups within PDQ classification-group are shown in [Table 3](#pone.0180014.t003){ref-type="table"}. Higher proportions of a low STR, reflecting the single patient having more tender than swollen joints, were seen across PDQ classification-groups with the highest proportions in the high PDQ classification group. A high STR, reflecting the single patient having more swollen than tender joints, was seen in limited proportions of patients across the PDQ classification-groups with the lowest proportion in the high PDQ classification-group. More patients with PsA than with RA had low STR.

10.1371/journal.pone.0180014.t003

###### Proportions n (%) of STR groups within PDQ classification-groups.

![](pone.0180014.t003){#pone.0180014.t003g}

                          Diagnosis    PDQ \<13 (n (%))   PDQ 13--18 (n (%))   PDQ \>18 (n (%))   p-value
  ----------------------- ------------ ------------------ -------------------- ------------------ --------------------------------------------
  Low STR \< 0,5          RA           601(61.4)          310 (60.0)           336 (67.0)         \<0.001
  PsA                     134 (71.3)   132 (75.4)         149 (78.8)                              
  Moderate STR 0.5--1.0   RA           317 (32.4)         181 (35.5)           151 (30.0)         0.101
  PsA                     48 (25.5)    39 (22.3)          37 (29.6)                               
  High STR \> 1.0         RA           61 (6.2)           26 (5.0)             15 (3.0)           0.045[\*](#t003fn002){ref-type="table-fn"}
  PsA                     6 (3.2)      4 (2.3)            3 (1.6)                                 

Chi square test was used to compare groups. Overall Chi-Square tests: RA, p = 0.03; PsA, p = 0.52.

\*Fisher\'s exact test

Logistic regression {#sec015}
-------------------

The results of the logistic regression analysis quantifying the risk of high pain rating are shown in [Table 4](#pone.0180014.t004){ref-type="table"}. The cut off point for the dependent variable 'VAS pain for PDQ-completers' was 39 mm. For each of the models, the high and the intermediate, the high and the low, and the intermediate and the low PDQ classification-groups were compared. Also the diagnoses were mutually compared. Of the a priori chosen confounders 'disease duration' was insignificant in the adjusted model 1 (p = 0.89) and was therefore omitted in the adjusted model 2. Results were robust across all models. The highest OR's for having at or above the median VAS pain score were seen in the high PDQ-classification-group compared with the low PDQ classification-group. Thus, it was more likely for the patients in the high PDQ classification group to have a VAS pain score at or above the median than for patients in the intermediate or low PDQ classification-group.

10.1371/journal.pone.0180014.t004

###### Logistic regression analysis for modeling high pain status (≥ median VAS pain of 39 mm).

![](pone.0180014.t004){#pone.0180014.t004g}

  [Odds ratio (95%CI)]{.ul}                                                   
  --------------------------- ----- ------------- ------ ------------- ------ -------------
  ***PDQgroup H vs*. *I***    2.9   (2.4--3.5)    2.9    (2.3--3.5)    2.9    (2.4--3.5)
  ***PDQgroup H vs*. *L***    9.6   (8.3--11.6)   10.2   (8.4--12.4)   10.4   (8.6--12.5)
  ***PDQgroup I vs*. *L***    3.4   (2.9--3.8)    3.6    (3.0--4.2)    3.6    (3.1--4.2)
  **PsA vs RA**               1.2   (1.0.-1.4)    1.6    (1.3--1.9)    1.5    (1.3--1.8)
  **SpA vs RA**               1.6   (1.4--1.9)    2.3    (1.2--2.3)    2.5    (2.0--3.0)
  **SpA vs PsA**              1.4   (1.1--1.6)    1.5    (1.2--1.9)    1.6    (1.3--2.0)

PDQgroup: painDETECT classification-group. H: high (\>18), I: intermediate (13--18), L: low (\<13).

Prior to regression analysis an analysis of interaction was performed; PDQgroup p\<0.001, Diagnosis p\< 0.001, PDQgroup\*Diagnosis p = 0.76.

Model 1 adjusted: A priori defined potential confounders: sex, age, disease duration, CRP, and Biological treatment (yes/no).

Model 2 adjusted: Omitting 'disease duration' (p = 0.89): sex, age, CRP, and Biological treatment (yes/no).

The patients with PsA and SpA were more likely to have a VAS pain score at or above the median compared to patients with RA.

Discussion {#sec016}
==========

Pain and pain phenotype prevalence {#sec017}
----------------------------------

This registry-based, nationwide cross-sectional study of Danish patients with inflammatory arthritis showed that despite intensive treatment and generally low disease activity scores, 63 percent reported clinical significant residual pain (VAS pain ≥ 30 mm). This number was 52 percent in the overall study population (n = 14339). Clinically acceptable levels of pain in patients with inflammatory diseases are, however, a matter of debate. Wolfe et al., including 12,090 patients with RA, reported the best cut-point for an acceptable level of pain to be 2.0 on a 10 cm VAS \[[@pone.0180014.ref034]\], whereas Tubach et al., in their study of 1,532 patients with different rheumatologic diagnoses, reported the patient acceptable symptom level to be 42 on a 0--100 scale for pain \[[@pone.0180014.ref035]\]. It, therefore, seems reasonably to conclude that clinically meaningful pain was present in a large proportion of the study population.

Of the subsample evaluated with the PDQ (n = 7054), more than 20% had a PDQ-score \> 18, indicating the presence of primarily neuropathic pain features, while 45--56% depending on diagnosis had a score \< 13 indicating the absence of such pain characteristics. In comparison to patients with RA and SpA, patients with PsA more frequently had a PDQ score \> 18 (28%) and less frequent a PDQ score \< 13 (45%). This observation was further substantiated by higher proportions of a low STR in the high PDQ classification-groups for RA and PsA. Furthermore significantly higher proportions of PsA patients had a low STR, whereas lower proportions had a high STR in comparison to RA.

This also indicated that pain phenotype in PsA patients is harder to distinguish based only on more conventional clinical indices and that other instruments such as the PDQ may be needed.

Overall these findings suggest that contributions from central pain mechanisms may be more prominent in patients with PsA. The existence of a preclinical phase in patients with PsA prior to the diagnosis of the disease has recently been reported \[[@pone.0180014.ref036]\]. This phase is characterized by nonspecific musculoskeletal symptoms, including joint pain, fatigue, and stiffness preceding the development of PsA; a symptom constellation not unlike the one found in patients with FM. In line, studies report more frequent concomitant FM based on self-report in this patient group \[[@pone.0180014.ref010]\]. Still, it could be argued that the reporting of more frequent concomitant FM in the PsA group has to do with the nature of the disease involving widespread enthesitis mimicking FM and thus compromising the validity of tools designed to capture FM, including clinical tender point examination. Contradicting this notion is the study by Marchesoni et al reporting tender point to be the most valid clinical discriminator to distinguish PsA from FM \[[@pone.0180014.ref037]\].

Characteristics of the different pain phenotypes {#sec018}
------------------------------------------------

Among PDQ-completers significantly and clinically relevant higher levels of pain, fatigue, and negative impact on global health were observed across PDQ classification-groups for all diagnoses with the poorest levels of PROs in the high PDQ classification-group (\>18). This tendency was also observed for the TJC and composite disease activity scores (DAS28 and ASDAS), which were found to be low in the low PDQ classification-group and moderate in the intermediate and high PDQ classification-groups. However, no clinically relevant group differences were observed in objective inflammatory indices (SJC, CRP) indicating a larger contribution from non-inflammatory factors to the observed disease activity scores in the high PDQ-group (\>18) across all diagnoses.

Doctor's perception of overall disease activity was strikingly lower than patients self-report and the difference found across pain phenotypes was only borderline clinically relevant reflecting that doctors primarily evaluate the overall disease activity based on more objective indices.

Association between pain status and PDQ {#sec019}
---------------------------------------

The logistic regression analysis for the presence of pain at or above the median VAS pain supported that a high PDQ score better explained the presence of high levels of pain than a low score. Thus, patients presenting with neuropathic pain features had a 10-fold higher risk of having high levels of pain.

Clinical implications {#sec020}
---------------------

In the absence of any diagnostic gold standards, mechanism-based pain classification is based on the assumption that this can be done clinically, based on identifiable and discriminatory patterns of symptoms and signs assumed to reflect the underlying pathophysiology. Current scientific evidence, however, suggests that both neuropathic pain and pain conditions characterised primarily by augmented central pain processing may share similar neurobiological underpinnings \[[@pone.0180014.ref038]\]. Given that these neurobiological underpinnings give rise to clinical symptoms, it is not surprising if centrally mediated pain and neuropathic pain may share common clinical features such as those captured by the PDQ. Substantiating this notion, striking phenotypic similarities has been demonstrated in patients with established peripheral neuropathy and FM when evaluated with the PDQ \[[@pone.0180014.ref016]\]. It could, therefore, be speculated that rather than indicating the presence of neuropathic pain, a high PDQ score in our patient population reflected the presence of a primarily central pain component, including concomitant fibromyalgia. It is well recognized that compared to individuals with localized or regional pain, patients with centralized pain syndromes, including FM, report a higher illness burden; higher pain intensity, more pronounced pain-related interference with everyday life, and higher levels of psychological distress \[[@pone.0180014.ref039]\]. In the original study by Freynhagen et al., introducing the PDQ to an unselected sample of 8000 patients with chronic low back pain, 37% were classified as having a primarily neuropathic pain component \[[@pone.0180014.ref012]\]. Also in this sample, a high PDQ score was found to be associated with more intense pain, more severe co-morbidity and poorer quality of life. From a critical point of view, it could be argued that a high score on the PDQ might simply be related to the tendency to report more symptoms in general, which might also be linked to psychosocial factors, or represent a non-specific finding in patients with more centralized pain syndromes.

Still, since pain is frequently used as a proxy for inflammation in the evaluation of rheumatic diseases, it is important to recognize that not all pain is inflammatory. Interestingly, the study indicated a more intensive level of treatment across PDQ classification-groups. Although there were no differences in the numbers of patients receiving biological treatment across PDQ classification-groups, patients in the high PDQ classification-group were more likely to have received more than one biological agent (PsA) and to have been changed back to DMARDs after having been treated with biological agents (RA). These findings further indicate that treatment failure is more prevailing in patients with signs of augmented central pain processing \[[@pone.0180014.ref040]\]. Previous reports of worse treatment outcome for RA and PsA patients with concomitant fibromyalgia support this observation \[[@pone.0180014.ref005];[@pone.0180014.ref041]\].

It has been proposed that disease duration is related to the development of pain hypersensitivity in RA \[[@pone.0180014.ref042]\]. The results of this study did not support this notion as no significant differences were found across the PDQ classification-groups. In contrast, a statistically significant predominance of female gender was observed in the high PDQ group across all diagnoses, indicating a higher frequency of central pain mechanisms among females. This finding is in accordance with the observed gender distribution in other pain conditions characterized by augmented central pain processing, for example, FM \[[@pone.0180014.ref043];[@pone.0180014.ref044]\].

Limitations {#sec021}
-----------

The study had some limitations: the data sampled from the DANBIO registry were not complete; however, considering the large sample size we find that the descriptive statistics were representative. The more than 7,000 patients accepting to participate in the PDQ-survey had higher ratings on VAS pain and other PRO's than those declining, which might have skewed the distribution of PDQ-scores. Detailed general demographic and clinical information, including information about possible comorbidities associated with neuropathic pain, were not obtainable in this registry-based study and may also have influenced the study findings. The study design being cross-sectional did not allow for advanced multivariable modelling, which could have added more unique information on association between certain variables or characteristics and pain phenotype. More prospective studies involving prognostic factor research are desirable.

Furthermore, although the PDQ has been used to assess neuropathic pain features as a proxy of central sensitization, the cut off values were established and validated in a sample of neuropathic pain patients with a clearly defined peripheral factor, e.g. polyneuropathy and post herpetic neuralgia. The traditional PDQ cut off values may therefore not be valid for the concept of central sensitization in patients with inflammatory disorders. However, aside from construct validity, our group has shown that the PDQ has acceptable psychometric properties, including unidimensionality, scaling properties and test-retest reliability when applied in patients with inflammatory arthritis (in review). Lastly, this registry-based study did not examine if patients also fulfilled the criteria for a diagnosis of FM; a pain condition that by many is considered to represent the upper end of a pain hypersensitivity continuum. However, the existence of a gradual transition from acute physiological pain to more chronic pain states driven by changes in neural processing in the central nervous system is increasingly being recognized \[[@pone.0180014.ref002]\]. Nociceptive pain and pain caused by central pain mechanisms should therefore not be regarded as exclusive categorical labels but rather as concurrent possible mechanistic contributors to the patient's pain. Because of the likely influence of pain hypersensitivity on clinically relevant outcomes, the entire clinical pain hypersensitivity spectrum among patients with inflammatory disorders should be captured. Instruments designed to assess underlying pain mechanisms, and not only symptom based instruments designed to diagnose FM, therefore seem to be of relevance for this patient population.

Conclusion {#sec022}
----------

In conclusion, more than 50% of this large Danish population of patients with inflammatory arthritis reported significant pain and among those who completed the PDQ, approximately 20% were classified as having primarily neuropathic pain features; a possible proxy for central sensitization. The PDQ-score was associated with composite disease activity scores and PROs, but not with "objective markers" of peripheral inflammation (CRP and swollen joint count). Patients with indication of a central pain mechanism were found to have a 10-fold higher risk of having a high pain level than those with an indication of non-neuropathic pain. Pain classification by PDQ in patients with inflammatory arthritis may assist the advancement of pain mechanism-based treatment approaches and alignment of the expected outcome of anti-inflammatory treatment.

Ethical considerations {#sec023}
----------------------

Patient consent was obtained on the touch screen prior to the redirection to the PDQ. According to Danish legislation, surveys do not require approval by Ethics Committees and registrations and publications of data from clinical registries do not require patient consent or approval by Ethics Committees. Approval was obtained from the Danish Data Protection Agency.

The authors wish to acknowledge the contributions of all participating patients and departments of Rheumatology in Denmark, The DANBIO registry, Zitelab ApS, and Database Consultant Christian Cato Holm, MSc.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
